Press Releases: Drug Discovery/Combinatorial Chemistry

Press releases
Browse

Press releases

Displaying 1..10 of 32 - per page Next page
Order by

NSAID DANGERS COULD BE REDUCED WITH TDS (R) DELIVERY

The U.S. FDA this week issued new guidelines for labeling of Non-Steroidal Anti-Inflammatory Drugs (NSAID) and Acetaminophen (Paracetemol) used for pain relief and fever reduction due to concerns about overdosing and co-administration with Alcohol. TDS wo More

Pharmalicensing highlights top 50 biotech and pharma dealmakers

New summary from Partneringdesk highlights trends in dealmaking from the top pharma and biotech companies More

Astex and Maybridge announce exclusive lead discovery collaboration

Collaboration will combine Astex's unique approach to structure-based screening with Maybridge's vast collection of proprietary chemistries More

Aventis Pharmaceuticals makes milestone payment to Astex

Astex Technology today announced the receipt of a milestone payment from Aventis Pharmaceuticals, as part of a structural biology research agreement focused on solving novel human cytochrome P450 Crystal Structures More

Morphochem names Alfred E. Seidel as CEO

Morphochem names Alfred E. Seidel as CEO. Dr Seidel will drive strategic change at the Company as it advances its products into clinical development. More

Astex appoints Director of Medicinal Chemistry

Dr David Rees becomes Director of Medicinal Chemistry at Astex More

ACCESS PHARMACEUTICALS, INC. ACQUIRES TARGETED THERAPEUTIC DIVISION OF BIOTECH AUSTRALIA

Key Acquisition Enhances ACCESS' Cancer Polymer Therapeutics Program And Expands Its Scientific Capabilities More

Astex announces Alzheimer's drug discovery collaboration with AstraZeneca

Agreement relates to the discovery of novel drugs against a key protein target implicated in Alzheimer's disease More

RiboTargets' exclusive licence with ASINEX extended

RiboTargets, the structure-based drug discovery company that develops novel cancer and anti-bacterial therapeutics, announced today that it has extended its exclusive license with ASINEX for a further three years. More

Amarin Corporation Announces Additional Positive Clinical Data For Miraxion To Treat Unresponsive Depression

Consistent data in three Phase IIa clinical trials in depression patients with melancholic characteristics More

Displaying 1..10 of 32 - per page Next page
Order by

Your selection

Industry sector: Drug discovery del; Combinatorial chemistry del

Browse By

Therapeutic target: Accident and Trauma; Allergy; Blood and forming organs; Cardiovascular; Central Nervous System; Dermatological; Endocrinology; Gastrointestinal; Genetic disorders; Genito-urinary; Hospital and Surgery; Immune related disorders; Infectious diseases; Metabolism; Musculoskeletal; Oncology; Oral Health; Other therapeutic; Respiratory; Sensory organ
Year: 2009; 2008; 2007; 2006; 2005; 2004; 2003; 2002; 2001; 2000; 1999

Products:	Partnering Search	Company Profiling	Deal Negotiation	PL Intelligence	Reports	Comparision
In-licensing:	Latest records	Industry Sector	Therapeutic Target	Search	Profile your company	Pharma partnering
Out-licensing:	Latest records	Industry Sector	Therapeutic Target	Search	Profile your company	Pharma partnering
Companies:	Profiled companies	Industry Sector	Therapeutic Target	Geographic Location	Search	Add your company
Reports:	Biotechnology	Business Development	Management	Market & Sales	Medical Devices	Pharmaceuticals
Jobs:	Pharmaceutical jobs	Browse jobs	Search for jobs	Create your CV	Employer profiles	Post your jobs
Forums:	Talk to an expert	Industry Gossip	Business Development	What's new	Reports	Services
News:	Deals & Alliances	Development	Financial Results	Financings	Intellectual Property	Regulatory
Events:	Pharma events	Calendar	Organizers	Featured events	Search
Articles:	Business Development	Technologies	Events	Legal and regulatory	Therapeutic
Deals:	Industry Sector	Therapeutic Target	Deals Date	Search	Reports	Press releases
About us:	Our Audience	Case Studies	Newsletter	Careers	FAQ	Contact us